Valneva (NASDAQ:VALN) Posts Earnings Results, Misses Estimates By $0.32 EPS

Valneva (NASDAQ:VALN) posted its quarterly earnings results on Wednesday. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.32), Zacks reports. Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%.

Valneva Stock Up 5.5 %

NASDAQ VALN traded up $0.37 during trading on Thursday, hitting $7.10. The company’s stock had a trading volume of 10,924 shares, compared to its average volume of 25,915. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. The company has a market cap of $576.95 million, a PE ratio of -54.88 and a beta of 1.93. The business’s 50 day simple moving average is $6.24 and its 200-day simple moving average is $5.60. Valneva has a fifty-two week low of $3.62 and a fifty-two week high of $9.50.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $17.00 price target on shares of Valneva in a report on Friday, February 28th.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.